SLC5A2 and type 2 diabetes mellitus: Given the growing disease burden of type 2 diabetes and other common diseases affecting hundreds of millions worldwide who may be treated with SGLT2 inhibitors, this study may eventually lead to more tailored treatments for a class of medication with growing popularity.